177 related articles for article (PubMed ID: 24982407)
1. The lack of evidence for correlation of pyruvate kinase M2 expression with tumor grade in non-small cell lung cancer.
Kobierzycki C; Pula B; Werynska B; Piotrowska A; Muszczynska-Bernhard B; Dziegiel P; Rakus D
Anticancer Res; 2014 Jul; 34(7):3811-7. PubMed ID: 24982407
[TBL] [Abstract][Full Text] [Related]
2. Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer.
Rzechonek A; Kaminska A; Mamczur P; Drapiewski A; Budzynski W
Adv Exp Med Biol; 2017; 955():51-57. PubMed ID: 27683215
[TBL] [Abstract][Full Text] [Related]
3. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring.
Schneider J; Neu K; Grimm H; Velcovsky HG; Weisse G; Eigenbrodt E
Anticancer Res; 2002; 22(1A):311-8. PubMed ID: 12017309
[TBL] [Abstract][Full Text] [Related]
4. Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients.
Werynska B; Pula B; Muszczynska-Bernhard B; Gomulkiewicz A; Piotrowska A; Prus R; Podhorska-Okolow M; Jankowska R; Dziegiel P
Exp Mol Pathol; 2013 Feb; 94(1):301-8. PubMed ID: 23064051
[TBL] [Abstract][Full Text] [Related]
5. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.
Hsu NY; Ho HC; Chow KC; Lin TY; Shih CS; Wang LS; Tsai CM
Cancer Res; 2001 Mar; 61(6):2727-31. PubMed ID: 11289154
[TBL] [Abstract][Full Text] [Related]
7. [Tripartite-motif protein 25 and pyruvate kinase M2 protein expression in non-small cell lung cancer].
Jing HZ; Qiu F; Chen SZ; Su L; Qu C
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Mar; 35(3):437-41. PubMed ID: 25818796
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
Wang ZX; Xue D; Liu ZL; Lu BB; Bian HB; Pan X; Yin YM
Int J Biochem Cell Biol; 2012 Jan; 44(1):200-10. PubMed ID: 22064247
[TBL] [Abstract][Full Text] [Related]
9. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Hsu NY; Wu JY; Liu X; Yen Y; Chen CY; Chou MC; Lin CH; Lee H; Cheng YW
Anticancer Res; 2011 Oct; 31(10):3475-81. PubMed ID: 21965764
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
11. P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.
Uramoto H; Sugio K; Oyama T; Hanagiri T; Yasumoto K
Anticancer Res; 2006; 26(2A):983-8. PubMed ID: 16619496
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Pyruvate Kinase M2 Expression with Clinicopathological Data in Ovarian Cancer.
Kobierzycki C; Piotrowska A; Latkowski K; Zabel M; Nowak-Markwitz E; Spaczynski M; Kedzia W; Pula B; Podhorska-Okolow M; Dziegiel P
Anticancer Res; 2018 Jan; 38(1):295-300. PubMed ID: 29277786
[TBL] [Abstract][Full Text] [Related]
14. Wnt3 gene expression promotes tumor progression in non-small cell lung cancer.
Nakashima N; Liu D; Huang CL; Ueno M; Zhang X; Yokomise H
Lung Cancer; 2012 May; 76(2):228-34. PubMed ID: 22070884
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
[TBL] [Abstract][Full Text] [Related]
16. EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions.
Meert AP; Martin B; Verdebout JM; Feoli F; Mascaux C; Ninane V; Sculier JP
Anticancer Res; 2006; 26(1A):135-8. PubMed ID: 16475689
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Milas I; Komaki R; Hachiya T; Bubb RS; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
Clin Cancer Res; 2003 Mar; 9(3):1070-6. PubMed ID: 12631609
[TBL] [Abstract][Full Text] [Related]
18. [Expression of HDGF and its implication in stage I non-small cell lung cancer].
Zhou SJ; Xu SF; Zhang HQ; Liu ZD
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):927-30. PubMed ID: 18478933
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
[TBL] [Abstract][Full Text] [Related]
20. PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression.
Lei B; Liu S; Qi W; Zhao Y; Li Y; Lin N; Xu X; Zhi C; Mei J; Yan Z; Wan L; Shen H
Histopathology; 2013 Nov; 63(5):696-703. PubMed ID: 24025073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
